Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight | Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx, Lenus

Posted on
by

Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight | Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx, Lenus
The Epidermolysis Bullosa Market size was valued at USD 2,400 Million in the year 2021 and the report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the 7MM.

The Epidermolysis Bullosa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.  

 

DelveInsight’s “Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epidermolysis Bullosa Market Insights

 

Some of the key facts of the Epidermolysis Bullosa Market Report: 

  • The Epidermolysis Bullosa market size was valued at USD 2,400 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In November 2023, Krystal Biotech disclosed that the Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA) Committee CHMP for VYJUVEK to address dystrophic epidermolysis bullosa (DEB) has been accepted and is presently undergoing CHMP scrutiny. An opinion from CHMP is expected in the latter part of 2024.
  • In September, 2023, Abeona Therapeutics has filed a Biologics License Application (BLA) for EB101 with the FDA. Should it receive Priority Review designation, the company anticipates potential approval of the BLA in the second quarter of 2024.
  • The exact number of individuals impacted by epidermolysis bullosa remains uncertain, as per Stanford Medicine (2023). However, an estimated 25,000 to 50,000 people in the United States are believed to be affected by this condition.
  • The overall prevalent population of Epidermolysis Bullosa across the 7MM was approximately 47,000 cases in 2023. These cases are expected to rise during the study period from 2020 to 2034.
  • In 2023, the prevalent population of epidermolysis bullosa in Japan was estimated to be around 2,000 cases. It is expected that these cases will increase by the year 2034.
  • In 2023, the total prevalent cases of Epidermolysis Bullosa in the United States were approximately 31,000.
  • Key Epidermolysis Bullosa Companies: Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx/ Lenus Therapeutics, Castle Creek Biosciences, Ishin Pharma, RHEACELL GmbH & Co. KG, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., TWi Biotechnology, Inc., Castle Creek Biosciences, Holostem Terapie Avanzate s.r.l., and others 
  • Key Epidermolysis Bullosa Therapies: FILSUVEZ, B-VEC, EB-101, FCX-007, RGN-137, D-Fi (dabocemagene autoficel), ISN001, APZ2-OTS, PTW-002, AGLE 102, ALLO-ASC-SHEET, AC-203, FCX-007, Transplantation, and others

 

Epidermolysis Bullosa Overview

Epidermolysis bullosa (EB) is a rare genetic disorder characterized by fragile skin that is prone to blistering and tearing even with minor friction or trauma. It is caused by mutations in genes responsible for producing proteins that help anchor the layers of skin together. As a result, individuals with EB have skin that is extremely delicate and prone to blistering, leading to painful open wounds and sores.

 

Get a Free sample for the Epidermolysis Bullosa Market Report:

https://www.delveinsight.com/report-store/epidermolysis-bullosa-market

 

Epidermolysis Bullosa Market  

The dynamics of the Epidermolysis Bullosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

“In June 2022, the European Commission (EC) approved FILSUVEZ for the treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older”

 

Epidermolysis Bullosa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Epidermolysis Bullosa Epidemiology Segmentation:

The Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Epidermolysis Bullosa
  • Prevalent Cases of Epidermolysis Bullosa by severity
  • Gender-specific Prevalence of Epidermolysis Bullosa
  • Diagnosed Cases of Episodic and Chronic Epidermolysis Bullosa

 

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Epidemiological Insights

 

Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Epidermolysis Bullosa Therapies and Key Companies

  • FILSUVEZ: Amryt Pharma
  • B-VEC: Krystal Biotech
  • EB-101: Abeona Therapeutics
  • FCX-007: Castle Creek Biosciences
  • RGN-137: RegeneRx/ Lenus Therapeutics
  • D-Fi (dabocemagene autoficel): Castle Creek Biosciences
  • ISN001: Ishin Pharma
  • APZ2-OTS: RHEACELL GmbH & Co. KG
  • PTW-002: Phoenicis Therapeutics
  • AGLE 102: Aegle Therapeutics
  • ALLO-ASC-SHEET: Anterogen Co., Ltd.
  • AC-203: TWi Biotechnology, Inc.
  • FCX-007: Castle Creek Biosciences
  • Transplantation: Holostem Terapie Avanzate s.r.l.

 

To know more about Epidermolysis Bullosa treatment, visit @ Epidermolysis Bullosa Medications

 

Epidermolysis Bullosa Market Drivers

  • The rise in the prevalence of epidermolysis bullosa
  • Robust clinical pipeline containing emerging drugs with novel RoA and MoA
  • Gene and cell therapies are also in the clinical stages of development for the treatment of epidermolysis bullosa
  • Increase funding support from organizations such as epidermolysis bullosa Research Partnership

 

Epidermolysis Bullosa Market Unmet Needs

  • Challenges in diagnosis
  • Lack of effective treatment
  • Challenges in the clinical trial
  • Poor disease understanding

 

Scope of the Epidermolysis Bullosa Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Epidermolysis Bullosa Companies: Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx/ Lenus Therapeutics, Castle Creek Biosciences, Ishin Pharma, RHEACELL GmbH & Co. KG, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., TWi Biotechnology, Inc., Castle Creek Biosciences, Holostem Terapie Avanzate s.r.l., and others
  • Key Epidermolysis Bullosa Therapies: FILSUVEZ, B-VEC, EB-101, FCX-007, RGN-137, D-Fi (dabocemagene autoficel), ISN001, APZ2-OTS, PTW-002, AGLE 102, ALLO-ASC-SHEET, AC-203, FCX-007, Transplantation, and others
  • Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies
  • Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Epidermolysis Bullosa Unmet Needs, KOL’s views, Analyst’s views, Epidermolysis Bullosa Market Access and Reimbursement 

 

Discover more about therapies set to grab major Epidermolysis Bullosa market share @ Epidermolysis Bullosa market forecast

 

Table of Contents 

1. Epidermolysis Bullosa Market Report Introduction

2. Executive Summary for Epidermolysis Bullosa

3. SWOT analysis of Epidermolysis Bullosa

4. Epidermolysis Bullosa Patient Share (%) Overview at a Glance

5. Epidermolysis Bullosa Market Overview at a Glance

6. Epidermolysis Bullosa Disease Background and Overview

7. Epidermolysis Bullosa Epidemiology and Patient Population

8. Country-Specific Patient Population of Epidermolysis Bullosa 

9. Epidermolysis Bullosa Current Treatment and Medical Practices

10. Epidermolysis Bullosa Unmet Needs

11. Epidermolysis Bullosa Emerging Therapies

12. Epidermolysis Bullosa Market Outlook

13. Country-Wise Epidermolysis Bullosa Market Analysis (2020–2034)

14. Epidermolysis Bullosa Market Access and Reimbursement of Therapies

15. Epidermolysis Bullosa Market Drivers

16. Epidermolysis Bullosa Market Barriers

17.  Epidermolysis Bullosa Appendix

18. Epidermolysis Bullosa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/